Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer’s Biosimilar Strategy Might Be Working

Executive Summary

Pfizer's biosimilar franchise  is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.

You may also be interested in...



Pfizer Signals Waning Interest In Biosimilars

Despite commercial success in biosimilars, Pfizer said it is more interested in investing in innovative therapeutics.

Pfizer Says JAKs Have Their Place Despite Xeljanz Safety Issues

Management said it remains confident in Xeljanz and believes next-generation JAKs will be sufficiently differentiated. Pfizer's Vyndaqel and biosimilars businesses emerged as new blockbusters.

Biosimilar Uptake Gains Momentum In The US

Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress. 

Related Content

Related Companies

UsernamePublicRestriction

Register

SC141551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel